"Use of Novel Combination Therapies in the Treatment of Advanced HR+/HER2- Breast Cancer"
•Evaluate the updated clinical guidelines for combination therapies in the treatment of HR+/HER2- advanced breast cancer patients
•Integrate clinical data regarding the use of CDK 4/6 inhibitors to treat HR+/HER2- advanced breast cancer, including appropriate subpopulations
•Mitigate toxicities associated with multi-drug treatment regimens to improve patient outcomes
•Recognize potential drug-drug interactions to plan effective and safe treatment regimens for each patient
Thursday, November 15, 2018 at 12:00pm
Fred and Pamela Buffett Cancer Center, 5.12.331
505 S 45th St, Omaha, NE 68106